Global Paediatric Interventional Cardiology Market Analysis to 2029

Featuring Medtronic, NeMED, GE Healthcare and Boston Scientific Among Others

The “Paediatric Interventional Cardiology Market Analysis by Device Type and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.

The paediatric interventional cardiology market size is estimated to be USD 1,581.3 million in 2021 and is expected to witness a CAGR of 11.18% during the forecast period 2022-2029.

Companies Mentioned:

  • St. Jude Medical Inc. (U.S.)
  • Medtronic Inc. (U.S.)
  • W.L. Gore & Associates Inc. (U.S.)
  • Edwards Lifesciences Corp (U.S.)
  • NuMED Inc. (U.S.)
  • Cordis Corporation (U.S.)
  • GE Healthcare (U.K.)
  • Siemens Healthcare (Germany)
  • Boston Scientific (U.S.)
  • Abbott Vascular (U.S.)

The increased rates of congenital heart disease and FDA initiatives to streamline the regulatory process, technical advances, which have resulted in the introduction of new and improved products is expected to drive the market.

However, changing stringency of regulatory procedures and presence of complex regulatory procedures is expected to restrain the market growth.

By Device Type

Based on device type, the market is segregated into transcatheter heart valves and congenital heart defect closure devices. In 2021, the congenital heart defect closure devices segment accounted for the highest revenue share due to a rising understanding of the importance of paediatric interventional cardiology devices and rising instances of congenital impairments.

Regional Markets

In 2021, Asia Pacific region accounted for the highest revenue in the paediatric interventional cardiology market and is expected to maintain its dominance during the forecast period. The increase in government funding for developing paediatric care facilities, and investments by prominent players in the APAC region. are all contributing to the market expansion.

Segmentation: Paediatric Interventional Cardiology Market Report 2021-2029

By Device Type (Revenue, USD Million)

  • Transcatheter Heart Valves
  • Congenital Heart Defect Closure Devices

By Region (Revenue, USD Million)

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

For more information about this report visit https://www.researchandmarkets.com/r/an873x

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.